Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition Journal Article


Authors: Pianko, M. J.; Devlin, S. M.; Littmann, E. R.; Chansakul, A.; Mastey, D.; Salcedo, M.; Fontana, E.; Ling, L.; Tavitian, E.; Slingerland, J. B.; Slingerland, A. E.; Clurman, A.; Gomes, A. L. C.; Taur, Y.; Pamer, E. G.; Peled, J. U.; van den Brink, M. R. M.; Landgren, O.; Lesokhin, A. M.
Article Title: Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition
Abstract: Patients with multiple myeloma (MM) who achieve minimal residual disease (MRD) negativity after upfront treatment have superior outcomes compared with those who remain MRD1. Recently, associations have been shown between specific commensal microbes and development of plasma cell disorders. Here, we report the association between intestinal microbiota composition and treatment outcome in MM. Microbiota composition of fecal samples collected from 34 MM patients after induction therapy and at the time of flow cytometry–based bone marrow MRD testing was determined by 16S ribosomal RNA sequencing. We observed a higher relative abundance of Eubacterium hallii in the 16 MRD2 patients relative to the 18 MRD1 patients. No association was observed between microbial relative abundance and autologous stem cell transplantation history or MM paraprotein isotype. No differences in microbiota a diversity were observed between MRD2 and MRD1 patients. The potential association of microbiota composition with treatment response in MM patients is an important parameter for additional correlative and clinical investigation. © 2019 by The American Society of Hematology
Journal Title: Blood Advances
Volume: 3
Issue: 13
ISSN: 2473-9529
Publisher: American Society of Hematology  
Date Published: 2019-07-09
Start Page: 2040
End Page: 2044
Language: English
DOI: 10.1182/bloodadvances.2019032276
PROVIDER: scopus
PMCID: PMC6616258
PUBMED: 31289031
DOI/URL:
Notes: Source: Scopus
Altmetric Score